New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
05:19 EDTRDS.A, WOPEYShell reduces interest in Woodside Petroleum by 156.5M shares
Shell (RDS.A) announced the sale of a total of approximately 156.5M shares in Woodside Petroleum (WOPEY) representing a total estimated value to Shell of around $5B on an after tax basis. The sale, which represents 19% of Woodside's issued share capital, is through an underwritten sell-down to equity market investors and a selective share buy-back by Woodside. Shell's subsidiary, Shell Energy Holding Australia, or SEHAL, has mandated two investment banks to sell 78.27M shares in Woodside, through an underwritten sell-down at a price of A$41.35 per share. This part of the sale represents around 9.5% of the issued capital in Woodside, with the shares to be sold to a range of equity market investors. The sell-down is expected to complete on June 18. Under an agreement with SEHAL, Woodside will also buy-back 78.27M of its shares from SEHAL at a price of $34.24 per share. The buy-back price per share has been split into a dividend component of $26.29 per share and a capital component of $7.95 per share, as agreed with the Australian Taxation Office in a private ruling. SEHAL will receive franking credits on the dividend component with the effect that no further tax is payable by SEHAL on the dividend component. Completion of the buy-back will be subject to limited conditions, including consent under a number of Woodside's facility agreements, an independent expert opinion and Woodside shareholder approval. Completion of the buy-back is expected in early August.
News For A;WOPEY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
10:12 EDTAHigh option volume stocks
High option volume stocks: A RS ALXN AVGO TFM PLKI JNPR VGK GDOT
08:38 EDTAAgilent authorizes repurchase of up to $1.14B of common stock
Agilent Technologies announced that its board of directors has approved a new share repurchase program. The 2015 Stock Repurchase Program authorizes the purchase of up to $1.14B of the companyís common stock through and including Nov. 1, 2018. The new program will commence, at the option of the company, on either Nov. 1, 2015, or the date on which the company completes the purchase of $365M of common stock under the existing stock repurchase program in fiscal 2015. Upon commencement, the new repurchase program replaces Agilentís existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs.
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use